Navigation Links
Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health
Date:2/25/2008

NEW YORK, Feb. 25 /PRNewswire/ -- Care to Care, a specialty Radiology Benefit Management (RBM) company, announced today that it has signed Touchstone Health HMO Inc. as a client. As a result of this new partnership, Care to Care's client portfolio has grown to over 700,000 lives.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080225/NYM113LOGO )

"Care to Care is excited and flattered to be selected as the Radiology Benefit Manager for Touchstone Health. They are a rapidly expanding Medicare Advantage Plan and we look forward to many long years of a great partnership," says Martin Farbenblum, Chairman of Care to Care.

"Touchstone Health selected Care to Care based on their expertise in Medicare and their flexibility to customize a plan to meet our unique needs. We anticipate a long relationship as we grow," says Touchstone Health's Chief Medical Officer Dr. Steven Arnold.

About Touchstone Health

Touchstone Health, headquartered in New York City, is an HMO focused on the Medicare market. Touchstone Health currently has Medicare beneficiaries in the Bronx, Kings, Queens, Richmond, Orange, Westchester, Broome, Chenango, Delaware & Onondaga counties. Benefits are available to anyone enrolled in both Medicare Part A and B and continue to pay their Medicare applicable premiums.

Touchstone Health is a privately held company owned and advised by, among other investors, Lehman Brothers Venture Capital, Essex Woodlands Health Ventures and Steven Wiggins. The company was originally formed to manage the medical services of enrollees of other HMOs operating in the federal Medicare program. During 2007, the company received an HMO license and no longer contracts with other HMOs. Touchstone prides itself on its local focus and customer service.

For more information about Touchstone Health, please visit the company's website at

SOURCE Care to Care
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Medical Services Begins Working With United States Companies for Distribution of Its Products
4. Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base
5. Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market
6. New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine
7. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
8. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
9. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
10. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... today announced a collaboration with University of California, ... test ImmunoPulse™ IL-12 as an immunotherapy in dogs ... the canine study are to advance the understanding ... and validate key clinical biomarkers. ...
(Date:6/1/2015)... Calif. , June 1, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... a Phase 2 clinical trial of AST-VAC1 in ... leukemia (AML). AST-VAC1 is the Company,s autologous (using ... cancer vaccine. AML is the most common form ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/31/2015)... Grow Med University (GMU) is a free, ... at their own pace and dip into the rich ... both scientific and other informative articles, to hone their ... harvest yet! , The medical marijuana industry is ... in the U.S. and a slew of other businesses ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Grow Med University: a Brand New Online Hydroponics Course 2
... ATLANTA, Sept. 24 GeoVax Labs, Inc. ... company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), ... in the recently completed Phase 3 trial in Thailand of ... for Infectious Diseases. The completed study represents the first HIV/AIDS ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a ... , Stem Cell Therapeutics Markets ... Political and business events presage change for stem cell ... lift federal funding restrictions on stem-cell research. The U.S. Congress has ...
... , , , ... CALP ), a leading provider of tools and services ... of XenoLight Rediject reagents at the World Molecular Imaging ... in an expanding range of XenoLight reagents for Caliper,s IVIS optical ...
Cached Biology Technology:Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 2Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 3Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 4Reportlinker Adds Stem Cell Therapeutics Markets Report 2Reportlinker Adds Stem Cell Therapeutics Markets Report 3Reportlinker Adds Stem Cell Therapeutics Markets Report 4Reportlinker Adds Stem Cell Therapeutics Markets Report 5Reportlinker Adds Stem Cell Therapeutics Markets Report 6Reportlinker Adds Stem Cell Therapeutics Markets Report 7Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 3
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Louisiana, US - Alligators display the same loyalty to ... in Molecular Ecology . The ten-year-study by scientists from ... of females chose to remain with their partner, often for ... Ruth Elsey, Tracey Tuberville and Stacey Lance, spent a decade ...
... in Spanish . , Individuals who follow ... grains and fish- appear less likely to develop depression, according ... the October issue of Archives of General Psychiatry . ... to be lower in Mediterranean than Northern European countries, according ...
... , This release is available in German . ... selectively transcribe parts of the DNA that makes up its genome ... proteins synthesized by a cell in turn determines its structure and ... crucial that the appropriate stretches of DNA are transcribed in each ...
Cached Biology News:Loyal alligators display the mating habits of birds 2Mediterranean diet associated with reduced risk of depression 2How RNA polymerase II gets the go-ahead for gene transcription 2How RNA polymerase II gets the go-ahead for gene transcription 3
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: